Traders should monitor the tender offer expiration on August 26, 2026, and any HSR clearance updates. The acquisition is a strategic pipeline expansion for argenx, but the lack of a disclosed total deal value limits precise financial impact assessment. Watch for any competing bids or regulatory delays.
Price Chart
Executive Summary
argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, a deal valued at an undisclosed total amount. The offer, supported by Forte's Board, is subject to a minimum tender condition of more than 50% of shares and HSR clearance, with no financing condition. This acquisition adds Forte's anti-CD122 antibody candidate FB102 to argenx's immunology pipeline, representing a strategic expansion into a new autoimmune target.
Key Facts
- argenx commenced a tender offer for Forte Biosciences at $77.00 per share in cash.
- The offer is subject to a minimum condition of more than 50% of shares tendered and HSR clearance.
- Forte's Board recommends the offer; no stockholder vote is required under Delaware law.
- The acquisition adds FB102, an anti-CD122 antibody, to argenx's pipeline.
- Offer expires at 11:59 p.m. ET on August 26, 2026, unless extended.
Financial Impact
$77.00 per share in cash; total deal value not disclosed in the press release.
Risk Factors
- Risk that the minimum tender condition or HSR clearance is not met, delaying or terminating the deal.
- Integration risk and uncertainty around FB102's clinical development and commercial potential.
- Potential stockholder litigation or competing acquisition proposals for Forte.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340172 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Institutional Cluster | $984.04 $995.77 | ▲ +1.19% | ▲ +1.69% | $918.23 (−6.69%) |
Aug 17, 2026 6w ago | 6-K | $987.84 $1,011.11 | ▲ +2.36% | ▲ +3.55% | $918.23 (−7.05%) |
Aug 6, 2026 8w ago | Press Release | $875.30 $856.94 | ▼ −2.10% | ▼ −3.31% | $918.23 (+4.91%) |
Jul 27, 2026 9w ago | 6-K | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 27, 2026 9w ago | Press Release | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 23, 2026 10w ago | Press Release | $924.60 $872.58 | ▼ −5.63% | ▼ −6.10% | $918.23 (−0.69%) |
Jul 16, 2026 11w ago | Press Release | $857.97 $924.60 | ▲ +7.77% | ▲ +9.44% | $918.23 (+7.02%) |
Jun 23, 2026 14w ago | 6-K | $853.40 $912.46 | ▲ +6.92% | ▲ +5.91% | $918.23 (+7.60%) |
Jun 3, 2026 17w ago | 6-K | $813.14 $862.18 | ▲ +6.03% | ▲ +9.85% | $918.23 (+12.92%) |
May 8, 2026 20w ago | Press Release | $813.28 $776.26 | ▼ −4.55% | ▼ −4.47% | $918.23 (+12.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access